X0508 4 2024-07-24 0001368514 ADMA BIOLOGICS, INC. ADMA 0002030561 Tade Brad L. C/O ADMA BIOLOGICS, INC. 5800 PARK OF COMMERCE BLVD. NW BOCA RATON FL 33487 true CFO and Treasurer false Common Stock 2024-07-24 4 A 0 72400 0 A 214433 D Stock Option (right to buy) 13.58 2024-07-24 4 A 0 115100 0 A 2034-07-24 Common Stock 115100 115100 D These shares represent restricted stock units ("RSUs") that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan") subject to the reporting person's continued service as of the applicable vesting date. Includes, as of the transaction date, (i) 72,400 RSUs granted on July 24, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 75,000 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; (Continued from Footnote 2 above) (iii) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (iv) 17,033 shares acquired in open market purchases and pursuant to the vesting of RSUs. The options vest over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the grant date. /s/ Brad L. Tade, by Adam S. Grossman as Attorney-in-fact 2024-07-26